Unlocking the Next
Chapter of Kidney Care
Meet the Expert Series: Video On Demand-Prof. Merlin Thomas
What for you are important Renal Outcomes to remember in EMPA REG, and EMPA KIDNEY that demonstrates the benefit of SGLT2i in CKD?
Related Videos
1:31
EK22||CV Mortality and HHF and CV Death secondary endpoint did not reach statistical Significance in EMPA Kidney. How should we view this result in relation to the Other Empagliflozin trials?
6:42
EK22||Hypertensive, Newly Diagnosed with CKD not on SGLT2i, what is your usual approach managing this patient based on your Practice
1:31
EK22||In a Diabetic patient newly diagnosed with CKD not on SGLT2i, how is your practice initiating SGLT2i if patient is also not on RAASI?
08:35
EK22||How can we improve Shared Care Approaches for Specialist and Primary Care Physicians in managing patients with CKD and Cardio Renal and Metabolic conditions for better patient care?
Document ID: SC-ASK-00683